Skip to main content

Syndicate contenttumors

Avastin dramatically improves response, survival in deadly recurrrent glioblastomas

The targeted therapy Avastin, alone and in combination with the chemotherapy drug CPT-11, significantly increased response rates, progression-free survival times and survival rates in patients with a deadly form of brain cancer that had recurred.

Computational process zeroes in on top genetic cancer suspects

Johns Hopkins engineers have devised innovative computer software that can sift through hundreds of genetic mutations and highlight the DNA changes that are most likely to promote cancer. The goal is to provide critical help to researchers who are poring over numerous newly discovered gene mutations, many of which are harmless or have no connection to cancer.

Scientists identify gene that predicts post-surgical survival from brain metastasis of breast cancer patients

PHILADELPHIA -- Researchers at the National Cancer Institute have identified a gene that may play a role in breast cancer metastasis to the brain, according to a report in Molecular Cancer Research, a journal of the American Association for Cancer Research.

'Watchful waiting' is a viable option for prostate cancer patients with low-risk tumors

BOSTON -- Appropriately selected prostate cancer patients, including older men and men with small, low-risk tumors, may safely defer treatment for many years with no adverse consequences, according to a new study in the Journal of Clinical Oncology (JCO). Led by researchers at Beth Israel Deaconess Medical Center (BIDMC), the study appears online today.

NIH study reveals new genetic culprit in deadly skin cancer

Drawing on the power of DNA sequencing, National Institutes of Health researchers have identified a new group of genetic mutations involved in the deadliest form of skin cancer, melanoma.

Study reveals how a common virus eludes the immune system

Viruses have numerous tricks for dodging the immune system. In the September 7, 2009 issue of the Journal of Cell Biology, Stagg et al. reveal a key detail in one of these stratagems, identifying a protein that enables cyto¬megalovirus to shut down an antiviral defense (online August 31).

New hope for deadly childhood bone cancer

SALT LAKE CITY, Aug. 31, 2009 -- Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy.

Researchers identify new, cancer-causing role for protein

HOUSTON - The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.

Chemotherapy resistance: Checkpoint protein provides armor against cancer drugs

LA JOLLA, CA -- Cell cycle checkpoints act like molecular tripwires for damaged cells, forcing them to pause and take stock. Leave the tripwire in place for too long, though, and cancer cells will press on regardless, making them resistant to the lethal effects of certain types of chemotherapy, according to researchers at the Salk Institute for Biological Studies.

Blood-flow metabolism mismatch predicts pancreatic tumor aggressiveness

PHILADELPHIA -- Researchers from Turku, Finland, have identified a blood-flow glucose consumption mismatch that predicted pancreatic tumor aggressiveness, according to results of a study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

Long-term tamoxifen use increases risk of an aggressive, hard to treat type of second breast cancer

SEATTLE -- While long-term tamoxifen use among breast cancer survivors decreases their risk of developing the most common, less aggressive type of second breast cancer, such use is associated with a more than four-fold increased risk of a more aggressive, difficult-to-treat type of cancer in the breast opposite, or contralateral, to the initial tumor.

UCSB scientists discover potential drug delivery system

(Santa Barbara, Calif.) -- -- Scientists at UC Santa Barbara have discovered a potential new drug delivery system. The finding is a biological mechanism for delivery of nanoparticles into tissue. The results are published in this week's Proceedings of the National Academy of Sciences.

How diarrheal bacteria cause some colon cancers revealed in mouse studies

Johns Hopkins scientists say they have figured out how bacteria that cause diarrhea may also be the culprit in some colon cancers. The investigators say that strains of the common Bacteroides fragilis (ETBF) dupe immune system cells into permitting runaway colon tissue inflammation, a precursor for malignant growth.

Some brain tumors may be mediated by tiny filament on cells

UCSF scientists have discovered that a tiny filament extending from cells, until recently regarded as a remnant of evolution, may play a role in the most common malignant brain tumor in children.

Some skin cancer may be mediated by primary cilia activity

Tiny, solitary spikes that stick out of nearly every cell in the body play a central role in a type of skin cancer, new research has found. The discovery in mice shows that the microscopic structures known as primary cilia can either suppress or promote this skin cancer, depending on the mutation triggering the disease.



About us

Science Blog was started in August 2002. It lives, breathes and eats press releases from research organizations around the globe. Most of what you read here are press releases from the outfits named in the stories themselves. Got a news story you think belongs here? Let's talk. The other half of the equation is blog posts from readers like you. So if you have an interest in science, please register and join others like you in an ongoing, vibrant dialog about what makes the world tick. Meantime, please take a minute to read our Privacy Policy and Site Disclaimer.


Premium Drupal Themes by Adaptivethemes